| Name | Title | Contact Details |
|---|
Founded by Chief Executive Officer Sam Solakyan, Global Holdings, Inc. has excelled in its journey in becoming leaders in each of the industries it has a presence in. Their main responsibility lies in providing their clients with the most premiere level of service. More than just your typical holdings group, Global is a multifaceted company with financial assets and ownership in the radiology, pharmaceuticals, and medical billing and collections industries. Instead of merely buying and selling companies like other holdings groups, Global searches for the less desirable companies with hidden potential and applies its knowledge and expertise in the management field and aids in the recreation of a company that once was not.
Carepartners Health Services is a Asheville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Today, Dynex designs and manufactures a full range of automated workstations, laboratory instruments, and associated consumables that enable scientists and clinicians to make breakthrough discoveries, earlier, more-accurate diagnoses - innovations to
Valued Relationships (VRI) is a Franklin, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.